Literature DB >> 17938525

Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis.

Shusuke Yagi1, Masashi Akaike, Shuji Ozaki, Chikako Moriya, Kyoko Takeuchi, Tomoko Hara, Mitsunori Fujimura, Yuka Sumitomo, Takashi Iwase, Yasumasa Ikeda, Ken-ichi Aihara, Takehiko Kimura, Takeshi Nishiuchi, Masahiro Abe, Toshio Matsumoto.   

Abstract

AL amyloidosis is a disease in which immunoglobulin L chain is deposited in multiple organs, and the prognosis of cardiac amyloidosis is extremely poor. Although several treatments based on that for multiple myeloma, have been performed, there is no clear evidence that cardiac function is improved. We report a case of AL cardiac amyloidosis with moderate cardiac dysfunction for which we performed autologous peripheral blood stem cell transplantation (auto-PBSCT) in combination with high-dose melphalan therapy. This treatment resulted in significant improvement in cardiac function and good prognosis for about 3.5 years after the diagnosis. Therefore, auto-PBSCT is a possible option as up-front therapy for AL cardiac amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938525     DOI: 10.2169/internalmedicine.46.0142

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.

Authors:  Marit Mejhert; Robert Hast; Benngt Sandstedt; Izabella Janczewska
Journal:  BMJ Case Rep       Date:  2011-08-17

2.  Soluble tumour necrosis factor-alpha receptor improved the function, hypertrophy, and granular sparkling appearance of the left ventricular myocardium in systemic amyloid A amyloidosis: a case report.

Authors:  Sawa Miyagawa; Tadashi Miyamoto; Yukihito Sato
Journal:  Eur Heart J Case Rep       Date:  2020-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.